New trial + clinical hiring Started a Phase 3 trial (NCT07424677, actual start Aug 11, 2026); 2 clinical-operations roles open. ClinicalTrials.gov NCT07424677 (Aug 11, 2026)Evidence (1 event)
Aug 11, 2026 · ClinicalTrials.gov NCT07424677 leadSponsor.name='Zydus Therapeutics Inc.'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-11,type:ACTUAL}; studyFirstPostDate=2026-02-20; briefTitle='Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy'
Trial start Phase 3: Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy source ↗
Trial start Phase 3: Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes source ↗
Trial start Phase 2: Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis source ↗
Trial start Phase 1: Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease source ↗
Trial start Phase 3: Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis source ↗
Trial start Phase 2: Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US source ↗
Trial start Phase 2/Phase 3: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis source ↗
Trial start Phase 1: Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease source ↗
Trial start Phase 2: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis source ↗
Trial start Phase 1: A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function source ↗
Trial start Phase 1: Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function source ↗
Trial start Phase 1: Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male Subjects source ↗
Trial start Phase 1: A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers source ↗
Trial start Phase 2: Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis source ↗
Trial start Phase 2: Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD) source ↗
Trial start Phase 2: Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII) source ↗
Trial start Phase 2: Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis source ↗
Trial start Phase 2: Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis source ↗
Trial start Phase 2: Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL source ↗
Upcoming milestones
Dec 31, 2026 (ESTIMATED) · Phase 1 · Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease · NCT05045482
Dec 31, 2026 (ESTIMATED) · Phase 1 · Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease · NCT06825559
Apr 18, 2027 (ESTIMATED) · Phase 3 · Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis · NCT06427395
2028-03 (ESTIMATED) · Phase 2 · Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis · NCT07023835
2028-07 (ESTIMATED) · Phase 3 · Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy · NCT07424677
2032-11 (ESTIMATED) · Phase 3 · Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes · NCT07216235
Estimated primary completion per ClinicalTrials.gov. Dates move.
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
